TRACON Pharmaceuticals Stock Forecast, Price & News NASDAQ:TCON

The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share . It can also be calculated by dividing the company’s Market Cap by the Net Profit. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 100% Sell. Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.

• Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
• Analysts tracking TCON have forecast the quarterly EPS to shrink by -0.26 per share this quarter, while the same analysts predict the annual EPS to hit -$0.86 for the year 2023 and up to -$0.97 for 2024.
• The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
• It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting https://1investing.in/ of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. The ruling says that TRACON Pharmaceuticals has no right to future economics with I-Mab.

TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

• Current records show that the company has 22.31M in outstanding shares.
• 52 week high is the highest price of a stock in the past 52 weeks, or one year.
• All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.
• That ruling determines that I-Mab doesn’t have to pay any damages to TRACON Pharmaceuticals.

News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted.

Zacks Research is Reported On:

Companies to develop and commercialize innovative products in the United States. The company’s drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies. Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give TCON a short term outlook of 50% Buy on average.

As a general rule, the price of a T-bills moves inversely to changes in interest rates. Tracon Pharmaceuticals Inc. shares slid 45% in premarket trade Friday, after the cmpany said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent committee. TRACON Pharmaceuticals Inc., which has a market valuation of $22.63 million, is expected to release its quarterly earnings report May 09, 2023 – May 15, 2023. Analysts tracking TCON have forecast the quarterly EPS to shrink by -0.26 per share this quarter, while the same analysts predict the annual EPS to hit -$0.86 for the year 2023 and up to -$0.97 for 2024. In this case, analysts estimate an annual EPS growth of 38.10% for the year and -12.80% for the next year.

How has TCON performed historically compared to the market?

That shoots down its attempt at claiming $200 million in damages from I-Mab. However, I-Mab will have to pay $13.5 million in TCON’s legal fees. The bad news for TCON stock comes from a legal ruling favoring I-Mab. That ruling determines that I-Mab doesn’t have to pay any damages to TRACON Pharmaceuticals. TRACON Pharmaceuticals’ stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%).

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. Current records show that the company has 22.31M in outstanding shares. The insiders’ percentage holdings are 1.50% of outstanding shares while the percentage share held by institutions stands at 45.90%.

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

This suggests a possible upside of 1,150.3% from the the four cx core competencies‘s current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

As of this writing, more than 635,000 shares of the stock have changed hands. For comparison, the company’s daily average trading volume is about 75,000 shares. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

How big is TRACON Pharmaceuticals Inc?

Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown. The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter.

Intraday data delayed at least 15 minutes or per exchange requirements. TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelio… Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades.

What is TCON stock price target?

MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations. However, based on the arbitration award, I-Mab will bear a portion of Tracon’s legal fees and costs of about $13.5M. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. TRACON Pharmaceuticals and I-Mab signed a collaboration agreement for the development of CD73 antibody uliledlimab.

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. A look at the daily price movement shows that the last close reads $1.78, with intraday deals fluctuated between $0.805 and $1.20.

The agreement was ended early with the agreed on $9 million fee plus interest. TRACON Pharmaceuticals has a short interest ratio (“days to cover”) of 0.9, which is generally considered an acceptable ratio of short interest to trading volume. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to one analyst, the rating for TCON stock is “Strong Buy” and the 12-month stock price forecast is $12.0. Represents the company’s profit divided by the outstanding shares of its common stock.

In the past three months, TRACON Pharmaceuticals insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $243,764.00 in company stock and sold $0.00 in company stock. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. What analysts recommend for TCON stock, on a scale from 1 to 5.

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Discuss news and analysts’ price predictions with the investor community. MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology , Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.

10 people have searched for TCON on MarketBeat in the last 30 days. TRACON Pharmaceuticals does not have a long track record of dividend growth.

No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind. The report also sheds light on the evaluation of growth opportunities, challenges, market threats and constraining factors of the TCON Chip Market. It studies local regional as well as global market and emerging segments, and market dynamics also.

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time. CompareTCON’s historical performanceagainst its industry peers and the overall market.

JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk.

Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days.